文献速递糖尿病

hs-CRP与血清淀粉样P成分在预测2型糖尿病患者全因死亡率中的协同关联

The Synergic Association of hs-CRP and Serum Amyloid P Component in Predicting All-Cause Mortality in Patients With Type 2 Diabetes.
PubMed 文献 · Diabetes Care · 2020-03-06

研究分析四个队列共2499例糖尿病患者(643例全因死亡),hs-CRP与SAP均独立关联全因死亡率(HR分别为1.46和0.82),仅当hs-CRP>2 mg/L时SAP≤33 mg/L才与死亡风险增加相关(HR 1.96),两标志物联合可改善ENFORCE和RECODe模型的预测能力。

要点

  • hs-CRP与SAP均独立关联2型糖尿病全因死亡率,方向相反。
  • 仅当hs-CRP>2 mg/L时,SAP≤33 mg/L与死亡风险增加相关(HR 1.96)。
  • 联合hs-CRP与SAP可显著改善ENFORCE和RECODe模型的预测能力。

核心结论

  • 在2型糖尿病中,hs-CRP与SAP与全因死亡率呈相反且协同的关联。
  • 联合使用两标志物可能改善真实临床环境中预测死亡风险的能力。

研究设计与样本

  • 分析四个队列共2499例糖尿病患者,其中643例全因死亡。
  • 使用ENFORCE和RECODe两个预测模型评估死亡率预测的改善。

主要发现

  • hs-CRP与全因死亡率独立关联,HR 1.46(95%CI 1.34-1.58),P<0.001。
  • SAP与全因死亡率独立关联,HR 0.82(95%CI 0.76-0.89),P<0.001。
  • hs-CRP>2 mg/L且SAP≤33 mg/L者较SAP>33 mg/L者死亡风险增加,HR 1.96(95%CI 1.52-2.54),P<0.001。
  • hs-CRP≤2 mg/L亚组中SAP≤33 mg/L与SAP>33 mg/L的死亡风险无显著差异,HR 1.20(95%CI 0.91-1.57),P=0.20。
  • hs-CRP与SAP分层交互作用P<0.001。

关键数值与推荐

  • SAP阈值33 mg/L,hs-CRP阈值2 mg/L。
  • ENFORCE和RECODe模型加入两标志物后判别与重分类指标改善均P<0.05。

临床怎么用

  • 作者认为,联合使用hs-CRP和SAP(可能与其他尚未揭示的标志物联合)可能改善真实临床环境中预测死亡风险的能力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Type 2 diabetes is characterized by increased death rate. In order to tackle this dramatic event, it becomes essential to discover novel biomarkers capable of identifying high-risk patients to be exposed to more aggressive preventive and treatment strategies. hs-CRP and serum amyloid P component (SAP) are two acute-phase inflammation proteins, which interact physically and share structural and functional features. We investigated their combined role in associating with and improving prediction of mortality in type 2 diabetes. RESEARCH DESIGN AND METHODS: Four cohorts comprising 2,499 patients with diabetes (643 all-cause deaths) were analyzed. The improvement of mortality prediction was addressed using two well-established prediction models, namely, EstimatioN oF mORtality risk in type 2 diabetiC patiEnts (ENFORCE) and Risk Equations for Complications of Type 2 Diabetes (RECODe). RESULTS: Both hs-CRP and SAP were independently associated with all-cause mortality (hazard ratios [HRs] [95% CIs]: 1.46 [1.34-1.58] [P < 0.001] and 0.82 [0.76-0.89] [P < 0.001], respectively). Patients with SAP ≤33 mg/L were at increased risk of death versus those with SAP >33 mg/L only if hs-CRP was relatively high (>2 mg/L) (HR 1.96 [95% CI 1.52-2.54] [P < 0.001] and 1.20 [0.91-1.57] [P = 0.20] in hs-CRP >2 and ≤2 mg/L subgroups, respectively; hs-CRP-by-SAP strata interaction P < 0.001). The addition of hs-CRP and SAP significantly (all P < 0.05) improved several discrimination and reclassification measures of both ENFORCE and RECODe all-cause mortality prediction models. CONCLUSIONS: In type 2 diabetes, hs-CRP and SAP show opposite and synergic associations with all-cause mortality. The use of both markers, possibly in combination with others yet to be unraveled, might improve the ability to predict the risk of death in the real-life setting.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Scarale MG, Copetti M, Garofolo M, et al. The Synergic Association of hs-CRP and Serum Amyloid P Component in Predicting All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes Care. 2020. PMID: 32144164. doi:10.2337/dc19-2489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。